| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012063812 |
| P356 | DOI | 10.2165/00023210-200822080-00005 |
| P698 | PubMed publication ID | 18601305 |
| P2093 | author name string | Filippo Bogetto | |
| Silvio Bellino | |||
| Erika Paradiso | |||
| P2860 | cites work | Affective instability as rapid cycling: theoretical and clinical implications for borderline personality and bipolar spectrum disorders | Q22242607 |
| Pharmacological interventions for people with borderline personality disorder | Q22252974 | ||
| Fluoxetine and impulsive aggressive behavior in personality-disordered subjects | Q28256655 | ||
| Ventricular arrhythmia following thioridazine poisoning | Q28328261 | ||
| Preventing lithium intoxication. Guide for physicians | Q28354303 | ||
| Long-term tolerability of lamotrigine: data from a 6-year continuation study | Q30891346 | ||
| Olanzapine: an updated review of its use in the management of schizophrenia | Q32058541 | ||
| Blood dyscrasias in clozapine-treated patients in Italy | Q33331692 | ||
| Quetiapine for the treatment of borderline personality disorder; an open-label study | Q33373008 | ||
| Divalproex sodium--review of prophylactic migraine efficacy, safety and dosage, with recommendations | Q33589302 | ||
| Anti-bipolar therapy: mechanism of action of lithium | Q33596950 | ||
| The biology of impulsivity and suicidality | Q33870852 | ||
| Psychopharmacology of borderline personality disorder | Q33870917 | ||
| Oxcarbazepine as an adjunct for schizophrenia | Q44915232 | ||
| Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. | Q45005469 | ||
| A practical approach to the treatment of patients with borderline personality disorder | Q33870929 | ||
| Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. | Q33897785 | ||
| The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. | Q33921539 | ||
| Tolerability and safety of fluvoxamine and other antidepressants | Q33995120 | ||
| Emergence of intense suicidal preoccupation during fluoxetine treatment | Q34033711 | ||
| Oxcarbazepine treatment of bipolar disorder | Q34223806 | ||
| Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder | Q34314831 | ||
| Efficacy of phenelzine and haloperidol in borderline personality disorder | Q34364669 | ||
| Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder | Q34423107 | ||
| New antiepileptic drugs: review on drug interactions | Q34503324 | ||
| Newer therapies in the drug treatment of epilepsy | Q34509364 | ||
| Oxcarbazepine in the treatment of affective and schizoaffective disorders | Q34533545 | ||
| Antiepileptic drugs: indications other than epilepsy. | Q34549201 | ||
| Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature | Q34549705 | ||
| Oxcarbazepine in the treatment of borderline personality disorder: a pilot study | Q34561187 | ||
| Fluoxetine in the treatment of borderline and schizotypal personality disorders | Q34592932 | ||
| EPS profiles: the atypical antipsychotics are not all the same | Q34605044 | ||
| What makes a drug a primary mood stabilizer? | Q34622357 | ||
| An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression | Q34642676 | ||
| Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. | Q34678989 | ||
| Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo | Q34689667 | ||
| Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group | Q34727272 | ||
| Pharmacotherapy for personality disorders | Q34749826 | ||
| Redefining mood stabilization | Q35036680 | ||
| Clinical use of quetiapine in disease states other than schizophrenia. | Q35057941 | ||
| Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability | Q35067640 | ||
| New anticonvulsants: a review of applications for the management of substance abuse disorders | Q35083318 | ||
| Lamotrigine in mood disorders | Q35169489 | ||
| Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. | Q35189338 | ||
| Drug treatment of the personality disorders | Q35264755 | ||
| Mood-stabilizers: the archeology of the concept | Q35592500 | ||
| Newer anticonvulsants in the treatment of bipolar disorder. | Q35830291 | ||
| Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy | Q35903458 | ||
| A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. | Q45005505 | ||
| Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder | Q45292059 | ||
| Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. | Q46465939 | ||
| Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study | Q46486037 | ||
| Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients | Q46616432 | ||
| Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia | Q46630465 | ||
| Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target | Q46783014 | ||
| The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia | Q47250230 | ||
| Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study | Q47299094 | ||
| Indications for carbamazepine in mental illness: atypical psychiatric disorder or temporal lobe syndrome? | Q48102050 | ||
| Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder | Q48371331 | ||
| Aggression, suicide, and serotonin: relationships to CSF amine metabolites | Q48942392 | ||
| Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. | Q50923455 | ||
| Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. | Q51127042 | ||
| Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. | Q51480368 | ||
| Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. | Q51765278 | ||
| Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. | Q51914417 | ||
| Efficacy of carbamazepine compared with other agents: a clinical practice survey. | Q52028917 | ||
| Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. | Q52071346 | ||
| Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. | Q53921466 | ||
| An open trial of valproate in borderline personality disorder | Q54001001 | ||
| Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. | Q54116859 | ||
| A preliminary trial of fluoxetine in refractory borderline patients. | Q54298517 | ||
| IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol | Q57739400 | ||
| Low-Dose Clozapine in Acute and Continuation Treatment of Severe Borderline Personality Disorder | Q60630837 | ||
| Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients | Q68631847 | ||
| Fluoxetine trial in borderline personality disorder | Q68855875 | ||
| Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo | Q68882306 | ||
| Response of borderline patients to loxapine and chlorpromazine | Q70225700 | ||
| Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol | Q70393229 | ||
| Divalproex sodium as a treatment for borderline personality disorder | Q70838435 | ||
| Electrocardiographic changes, disturbances of cardiac rhythm, and sudden deaths during treatment with phenothiazine drugs | Q72264054 | ||
| Clozapine treatment of borderline patients: a preliminary study | Q72300371 | ||
| Enhancement of GABAergic inhibition: a mechanism of action of benzodiazepines, phenobarbital, valproate and L-cycloserine in the cat spinal cord | Q72545961 | ||
| Pharmacological prevention of suicidal behaviour | Q72546381 | ||
| Haloperidol vs. phenelzine in continuation therapy of borderline disorder | Q72729648 | ||
| Remission of self-mutilation in a patient with borderline personality during risperidone therapy | Q73388093 | ||
| [Efficacy and tolerability of carbamazepine as the initial drug used in the treatment of epilepsy] | Q73427117 | ||
| Risperidone in comorbid borderline personality disorder and dysthymia | Q73552447 | ||
| [Fluoxetine in the treatment of borderline personality disorder] | Q74227787 | ||
| Using lithium | Q80122749 | ||
| [Chronic renal function disorders during lithium use] | Q80150711 | ||
| Efficacy, safety, and tolerability of oxcarbazepine monotherapy | Q80234572 | ||
| Aripiprazole pharmacotherapy of borderline personality disorder | Q83835265 | ||
| Aripiprazole | Q94460642 | ||
| Mood stabilization in the treatment of bipolar disorder: focus on quetiapine | Q36119897 | ||
| Atypical antipsychotics: newer options for mania and maintenance therapy | Q36158824 | ||
| Safety and tolerability of emerging pharmacological treatments for bipolar disorder | Q36199036 | ||
| Maintenance therapies in bipolar disorder: focus on randomized controlled trials | Q36210974 | ||
| A typical mood stabilizers: a "typical role for atypical antipsychotics. | Q36231863 | ||
| Treatment of bipolar mania with atypical antipsychotics | Q36310053 | ||
| Pharmacological treatment in the early phase of bipolar disorders: what stage are we at? | Q36395731 | ||
| Side effects of antiepileptics--a review | Q36686139 | ||
| A psychobiological perspective on the personality disorders | Q37541977 | ||
| Prediction of change in borderline personality disorder | Q38375850 | ||
| Central serotonin and impulsive aggression | Q38754771 | ||
| Pharmacotherapy of borderline personality disorder: a review. | Q38777785 | ||
| Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression | Q38777789 | ||
| Pharmacotherapy of borderline outpatients | Q39531300 | ||
| "Mood-stabilizers: the archeology of the concept"--by M Harris, S Chandran, N Chakraborty and D Healy: a commentary | Q40547398 | ||
| The serotonin system and aggressive personality disorder. | Q40761412 | ||
| A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy | Q40762464 | ||
| Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation | Q40857679 | ||
| Spontaneous hypertensive reactions with monoamine oxidase inhibitors | Q40859368 | ||
| Bipolar mood disorder: practical strategies for acute and maintenance phase treatment | Q41033533 | ||
| Fluoxetine in borderline personality disorder | Q41331092 | ||
| Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder | Q41449641 | ||
| Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder | Q41666081 | ||
| Comparative effectiveness of carbamazepine and propranolol for rage outbursts | Q42012648 | ||
| Divalproex sodium in the treatment of aggressive behavior | Q42282315 | ||
| Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. | Q42594537 | ||
| An open trial of sertraline in personality disordered patients with impulsive aggression. | Q42600119 | ||
| Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder | Q42672198 | ||
| Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. | Q42690745 | ||
| Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone | Q43563998 | ||
| A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. | Q43577338 | ||
| Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior | Q43818467 | ||
| Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study | Q43844462 | ||
| Treatment of borderline personality disorder with risperidone | Q43942534 | ||
| Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder | Q43994379 | ||
| Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. | Q43999471 | ||
| Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. | Q44235503 | ||
| Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design | Q44272770 | ||
| Quetiapine in the treatment of borderline personality disorder | Q44312622 | ||
| Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder | Q44513113 | ||
| Impulsivity and prefrontal hypometabolism in borderline personality disorder | Q44555835 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders | Q44646530 | ||
| Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia | Q44649979 | ||
| Olanzapine versus placebo in the treatment of borderline personality disorder | Q44742709 | ||
| Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode | Q44801076 | ||
| Borderline personality disorder in patients with bipolar disorder and response to lamotrigine | Q44801078 | ||
| P433 | issue | 8 | |
| P921 | main subject | borderline personality disorder | Q208166 |
| pharmacotherapy | Q701216 | ||
| P304 | page(s) | 671-692 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Efficacy and tolerability of pharmacotherapies for borderline personality disorder | |
| P478 | volume | 22 |
| Q50994774 | 'I think we're all guinea pigs really': a qualitative study of medication and borderline personality disorder. |
| Q37865934 | Antiepileptic drugs in the treatment of psychiatric disorders |
| Q37794836 | Borderline Personality Disorder: Considerations for Inclusion in the Massachusetts Parity List of “Biologically-Based” Disorders |
| Q22241838 | Borderline personality disorder and bipolar affective disorder. Spectra or spectre? A review |
| Q36443670 | Borderline personality disorder: current drug treatments and future prospects. |
| Q28237349 | Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital |
| Q39840681 | Impulsivity: current and future trends in pharmacological treatment |
| Q37935806 | Off-label use of atypical antipsychotics in personality disorders. |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q28247724 | The effects of sertraline on psychopathic traits |
| Q37446677 | Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder |
Search more.